TCT 2023 | ISAR-DESIRE 3: 10-Year Results

In-stent restenosis (ISR) remains the primary limitation of percutaneous treatment for coronary artery disease. The strategy to address this limitation involves the use of drug-eluting stents (DES) or drug-coated balloons (DCB), both of which have proven to be effective and safe therapeutic alternatives.

TCT 2023 | SWEDEHEART, evolución  a 5 años

Despite current recommendations, treating ISR continues to be a challenge, and clinical trial evidence is limited. 

The objective of the Prospective Randomized ISAR-DESIRE 3 Study was to investigate the long-term incidence of recurrent revascularization after the treatment of ISR with drug-eluting stents.

The primary endpoint (PEP) was the need for repeat target lesion revascularization (R-TLR), defined as any repeated revascularization procedure over the 10-year follow-up.

A total of 402 patients were randomized to receive treatment with plain balloon (PB), DCB, or DES. At 10 years, R-TLR was required for 204 lesions, of which 82 were in the PB group, 70 in the DCB group, and 52 in the DES group. During the first year of follow-up, the risk of R-TLR was reduced with the use of DCB (hazard ratio [HR] = 0.36 [95% confidence interval (CI): 0.24-0.54]) and DES (HR = 0.23 [0.14-0.38]) compared with PB.

Read also: TCT 2023 | VIVA Trial: TAVR vs. SAVR in Patients with Severe Aortic Stenosis and Small Aortic Annulus.

After the first year, the risk of R-TLR was reduced non-significantly with DCB (HR = 0.77 [0.51-1.16]) and significantly with DES (HR = 0.61 [0.39-0.95]). The risk of DCB versus DES was similar during (HR = 1.54 [0.89-2.69]) and after 1 year (HR = 1.26 [0.82 – 1.92]).

Conclusion

In summary, the total number of R-TLR events after 10 years of DES-ISR treatment is high. The use of DCB and, in particular, of DES, are both alternatives to reduce the need for initial revascularization and recurrent revascularization compared with PB.

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Recurrent Revascularization at 10 Years after Percutaneous Treatment of Drug Eluting Stent Restenosis.

Reference: Tobias Koch, MD et al TCT 2023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Morpheus Global Registry: Safety and efficacy of the long tapered BioMime™ Morph stent in complex coronary lesions

Percutaneous coronary intervention in long coronary lesions continues to represent a technical and clinical challenge, in which the use of conventional cylindrical stents may...

Hybrid Coronary Revascularization versus Conventional Bypass Surgery in Left Main Coronary Artery Disease

Significant left main coronary artery (LMCA) disease continues to represent a therapeutic challenge, particularly in patients with complex multivessel disease and high SYNTAX scores,...

Comparison of strategies: NMA of IVUS, OCT, or angiography in complex lesions

Percutaneous coronary intervention (PCI) in complex lesions continues to represent a technical challenge in contemporary interventional cardiology. Angiography, although it remains the most widely...

Dynamic Coronary Roadmap: does it really help reduce contrast use?

Contrast-induced nephropathy remains a relevant complication of percutaneous coronary interventions (PCI), particularly in patients with multiple comorbidities and complex coronary anatomies. Dynamic Coronary Roadmap...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Transcatheter Deep Vein Arterialization in Critical Limb Ischemia Without Revascularization Options

Chronic limb-threatening ischemia in patients without conventional revascularization options represents one of the most challenging scenarios within peripheral arterial disease, with 1-year major amputation...

Transcatheter Paravalvular Leak Closure: Mid-Term Outcomes and Prognostic Factors

Paravalvular leaks (PVL) are a frequent complication following surgical valve replacement, occurring in 5% to 18% of prosthetic valves. Incidence varies according to valve...

After a Major Bleeding Event in Atrial Fibrillation: When Should Left Atrial Appendage Closure Be Considered?

Atrial fibrillation (AF) in patients who experience a major bleeding event represents a complex clinical scenario in which percutaneous left atrial appendage closure (LAAC)...